相关实验视频

Updated: Jul 17, 2025

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

病例报告:在罕见的EGFR Exon 18突变NSCLC中对奥西默提尼布的持续治疗反应

Michael Cekay¹, Philipp F Arndt^1,2, Rio Dumitrascu¹

¹Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany.

Frontiers in oncology

|September 1, 2023

概括

奥西默提尼布有效地治疗了肺癌中罕见的EGFR Exon 18突变,达到12个月的缓解期. 这一案例突出了奥西默提尼布作为EGFR Exon 18 p.Glu709_Thr710delinsAsp突变非小细胞肺癌的潜在治疗方法.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

非小细胞肺癌 (NSCLC) 常常含有可用氨酸激酶抑制剂 (TKI) 治疗的驱动突变.
罕见的突变,如EGFR Exon 18删除插入变异,存在诊断和治疗方面的挑战.
解释不常见突变的临床意义对于有效的患者管理至关重要.

研究的目的:

报告第一例针对特定EGFR Exon 18删除插入突变 (p.Glu709_Thr710delinsAsp) 的奥西默蒂尼布治疗成功的病例.
评估Osimertinib在患有这种罕见突变的NSCLC患者的疗效和安全性.
讨论Osimertinib作为这种具有挑战性的突变的潜在治疗选择.

主要方法:

一个65岁的男性肺腺癌患者的病例报告.
最初的治疗是以为基础的化疗.
用Osimertinib进行二线治疗.
监测治疗反应和不良事件.

主要成果:

患者对标准化疗没有反应.
奥西默蒂尼布的使用导致了持续12个月的持续性部分缓解.
轻度血小板缺血是唯一的毒性,通过降低剂量来控制.

结论:

奥西默提尼布在治疗EGFR Exon 18 p.Glu709_Thr710delinsAsp突变的NSCLC中表现出显著的疗效.
这一案例表明奥西默提尼布是这种罕见突变的可行治疗选择.
需要对罕见EGFR突变的TKI进行进一步的研究.

关键词:

在EGFR的Exon 18插入.在EGFR突变的过程中,奥西默蒂尼布 (Osimertinib) 是一种药物.非小细胞肺癌是非小细胞肺癌.氨酸激酶抑制剂 (TKI) 的使用

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...